MO40-3 Impact of acquired RAS, BRAF and PIK3CA mutation at 8 weeks on the efficacy of anti- EGFR monoclonal antibodies in mCRC
Titel:
MO40-3 Impact of acquired RAS, BRAF and PIK3CA mutation at 8 weeks on the efficacy of anti- EGFR monoclonal antibodies in mCRC
Auteur:
Kudo, T. Kataoka, K. Yamada, T. Mori, K. Shiozawa, M. Takase, N. Ito, K. Eda, H. Kimura, K. Song, J. Matsuhashi, N. Miyasaka, T. Tajima, J. Beppu, N. Oi, Y. Yamazaki, K. Ikeda, M.